Drug Search Results
More Filters [+]

Nebivolol

Alternative Names: nebivolol, nebilet, bystolic, byvalson, vyduo, Nebivolol
Latest Update: 2024-09-20
Latest Update Note: Clinical Trial Update

Product Description

Nebivolol is a medication used in the management and treatment of hypertension. It is in the beta-blocker class of drugs. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK551582/)

Mechanisms of Action: ADRB1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Myocardial Infarction | Hypertension | Stroke

Known Adverse Events: Headache

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nebivolol

Countries in Clinic: China, United States, Unknown Location

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Hypertension

Phase 2: Glaucoma, Open-Angle

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NEB-027-23

P1

Not yet recruiting

Healthy Volunteers

2024-08-17

BTQ-1901-1902-201

P2

Completed

Hypertension|Glaucoma, Open-Angle

2022-03-31

CTR20191808

P3

Not yet recruiting

Hypertension

None

CTR20160005

P1

Not yet recruiting

Hypertension

None

Recent News Events